Equity · Healthcare
NRIX
NASDAQNurix Therapeutics (NRIX)
The line runs 26.61 USD on 12 August through 16.13 USD on 9 November, on a scale from 10 to 30. Days the market did not trade hold the previous close, flat.
- Market cap
- 1.8B USD
- P/E (TTM)
- 7.0
- Revenue, year to Nov 2025
- 84.0M USD
- EPS, diluted, year to Nov 2025
- −3.05 USD
- 52-week range
- 12 USD – 27.79 USD
- Avg volume
- 139.3K
- Mentions, 30 days
- 1
as of Nov 9, 2026
Have Nurix Therapeutics (NRIX) insiders bought or sold shares recently?
In the 90 days to 10 Nov 2026, Nurix Therapeutics insiders reported 12 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 30 Oct 2025, show no open-market purchase.
Form 4, 90 days to 10 Nov 2026, newest reported trade 4 Nov 2026
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 04 Nov 2026 | van Houte HansChief Financial Officer | Sell | 4,769 | 75K USD |
| 03 Nov 2026 | Ring ChristineChief Legal Officer | Sell | 6,113 | 158K USD |
| 02 Nov 2026 | Hansen GwennChief Scientific Officer | Sell | 1,452 | 39K USD |
| 02 Nov 2026 | Ring ChristineChief Legal Officer | Sell | 10,602 | 274K USD |
| 30 Oct 2026 | Hansen GwennChief Scientific Officer | Sell | 3,957 | 104K USD |
| 30 Oct 2026 | Ring ChristineChief Legal Officer | Sell | 3,957 | 104K USD |
| 30 Oct 2026 | van Houte HansChief Financial Officer | Sell | 2,834 | 74K USD |
| 15 Oct 2026 | Hansen GwennChief Scientific Officer | Sell | 1,452 | 36K USD |
| 14 Oct 2026 | GREGORY JULIA PDirector | Sell | 22,583 | 529K USD |
| 02 Oct 2026 | Ring ChristineChief Legal Officer | Sell | 5,786 | 134K USD |
| 02 Sep 2026 | Ring ChristineChief Legal Officer | Sell | 5,787 | 149K USD |
| 01 Sep 2026 | Hansen GwennChief Scientific Officer | Sell | 1,452 | 37K USD |
| Sold | 12 open-market sales | 70,744 | $1.71M |
10 other filings in the window: grants, exercises, tax withholding and transfers, not trades
| Reported | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 02 Nov 2026 | Hansen GwennChief Scientific Officer | Option exercise | 1,452 | 3K USD |
| 02 Nov 2026 | Ring ChristineChief Legal Officer | Option exercise | 5,786 | 50K USD |
| 30 Oct 2026 | Hansen GwennChief Scientific Officer | Option exercise | 10,182 | |
| 30 Oct 2026 | Ring ChristineChief Legal Officer | Option exercise | 10,182 | |
| 30 Oct 2026 | van Houte HansChief Financial Officer | Option exercise | 10,182 | |
| 15 Oct 2026 | Hansen GwennChief Scientific Officer | Option exercise | 1,452 | 3K USD |
| 14 Oct 2026 | GREGORY JULIA PDirector | Option exercise | 22,583 | 42K USD |
| 02 Oct 2026 | Ring ChristineChief Legal Officer | Option exercise | 5,786 | 50K USD |
| 02 Sep 2026 | Ring ChristineChief Legal Officer | Option exercise | 5,787 | 50K USD |
| 01 Sep 2026 | Hansen GwennChief Scientific Officer | Option exercise | 1,452 | 3K USD |
Which funds hold Nurix Therapeutics (NRIX)?
1 of the 45 institutional funds we track reported a Nurix Therapeutics position for the quarter ended 30 Sep 2026 — a combined 8.5M USD; the latest of those filings landed 06 Nov 2026.
| Fund | Position | Shares | Value | Shares q/q |
|---|---|---|---|---|
| Fisher Asset Management | Held (±25%) | 356,843 | 8.5M USD | −3.4% |
What has been filed or recorded for Nurix Therapeutics (NRIX)?
The filings we hold for Nurix Therapeutics, newest first: 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 31 Aug 2026. No next earnings date is announced in SEC filings yet.
| And | ||||
|---|---|---|---|---|
| 31 Aug 2026 | Quarterly earnings | Q3 2026 reported | EPS 4.73 USD | |
| 31 Aug 2026 | Financials | Total assets | 1.2B USD | at period end |
| 31 Aug 2026 | Financials | Total equity | 968.3M USD | at period end |
| 31 May 2026 | Quarterly earnings | Q2 2026 reported | EPS −0.81 USD | |
| 28 Feb 2026 | Quarterly earnings | Q1 2026 reported | EPS −0.79 USD | |
| 30 Nov 2025 | Annual report | FY 2025 reported | EPS −3.05 USD | |
| 30 Nov 2025 | Financials | Revenue | 84.0M USD | fiscal year |
| 30 Nov 2025 | Financials | Net income | −264.5M USD | fiscal year |
| 30 Nov 2025 | Financials | Diluted EPS | −3.05 USD | fiscal year |
| 31 Aug 2025 | Quarterly earnings | Q3 2025 reported | EPS −1.03 USD | |
| 31 May 2025 | Quarterly earnings | Q2 2025 reported | EPS −0.52 USD | |
| 28 Feb 2025 | Quarterly earnings | Q1 2025 reported | EPS −0.67 USD | |
| 30 Nov 2024 | Annual report | FY 2024 reported | EPS −2.88 USD |
What is Reddit saying about Nurix Therapeutics (NRIX)?
Reddit mentioned NRIX 1 times in the 30 days to 10 November 2026, in 1 of the communities we track. All of them were scored for sentiment: 0% read bullish, 0% bearish and 100% neither. Reddit data updated 10 November 2026.
30-day window, Method
How do Reddit mentions of Nurix Therapeutics (NRIX) compare with its price?
Share ↗
Which subreddits are talking about Nurix Therapeutics (NRIX)?
30 days
| Community | Share | Mentions | Net sentiment |
|---|---|---|---|
| r/wallstreetbets | 100% | 1 | +0.03 |
What do people ask about Nurix Therapeutics (NRIX)?
What did Nurix Therapeutics shares close at?16.13
Nurix Therapeutics closed at 16.13 USD on 9 Nov 2026, up 5.53% on the close before. That is the end-of-day price from Finazon, not a live quote.
What is Nurix Therapeutics’ market cap?1.8B
Nurix Therapeutics is worth 1.8B USD by market value as of 9 Nov 2026, which is the share price times the shares on issue from its SEC filings.
What is Nurix Therapeutics’ P/E ratio?7.0
Nurix Therapeutics has a price-to-earnings ratio of 7.0, as of 9 Nov 2026: the share price divided by what the company earned per share over the last four reported quarters. A higher number means the market pays more for each dollar of earnings.
What is Nurix Therapeutics’ revenue?84.0M
Nurix Therapeutics reported revenue of 84.0M USD for the year ended 30 Nov 2025, as filed with the SEC. See Filings
Have Nurix Therapeutics insiders bought or sold shares recently?12 sales
In the 90 days to 10 Nov 2026, Nurix Therapeutics insiders reported 12 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 30 Oct 2025, show no open-market purchase. A further 10 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders
Which funds own Nurix Therapeutics?1 of 45
1 of the 45 funds we track reported a Nurix Therapeutics position for the quarter ended 30 Sep 2026, per their SEC Form 13F filings. The largest reported position was Fisher Asset Management. See Funds
When did Nurix Therapeutics last report earnings?4.73
Nurix Therapeutics last reported earnings on 31 Aug 2026 for Q3 2026, with EPS of 4.73 USD; no next date is announced in SEC filings yet. See Filings
What is Reddit saying about Nurix Therapeutics?1 mentions
Nurix Therapeutics was mentioned 1 times in the last 7 days across the finance subreddits we track, and 1 times over the trailing 30 days. Of the 1 mentions scored for sentiment, 0% read bullish and 0% bearish. That is a social signal, not investment advice. See Reddit
Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.
References
- Finazonprior-day close, indicative (IEX-derived, not the official close), some closes dollar-rounded at the source
- TradingViewthe price chart widget, drawn by TradingView from their own data
- RedditReddit ingest across the tracked finance subreddits
- SEC EDGARForm 4 filings (insider transactions)
- SEC EDGAR13F filings
- SEC EDGARXBRL company facts, latest period ended 31 Aug 2026
- SEC EDGARreported earnings figures and scheduled report dates
- SEC EDGARValuation computed from SEC EDGAR filings